PRELUDE THERAPEUTICS Trademark

Trademark Overview


On Friday, May 31, 2019, a trademark application was filed for PRELUDE THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the PRELUDE THERAPEUTICS trademark a serial number of 88454849. The federal status of this trademark filing is REGISTERED as of Tuesday, December 6, 2022. This trademark is owned by Prelude Therapeutics Incorporated. The PRELUDE THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research for medical purposes in the fields of oncology, hematology, autoimmune diseases, and rare diseases; clinical research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research and development of pharmaceuticals and biopharmaceuticals for the treatment of cancer, hematological diseases, autoimmune diseases, and rare diseases; providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; genetic testing for scientific research; genetic research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; none of the foregoing in relation to or in the field of fertility services
prelude therapeutics

General Information


Serial Number88454849
Word MarkPRELUDE THERAPEUTICS
Filing DateFriday, May 31, 2019
Status700 - REGISTERED
Status DateTuesday, December 6, 2022
Registration Number6918640
Registration DateTuesday, December 6, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 15, 2022

Trademark Statements


Disclaimer with Predetermined Text"THERAPEUTICS"
Goods and ServicesResearch and development of drugs in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research for medical purposes in the fields of oncology, hematology, autoimmune diseases, and rare diseases; clinical research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; scientific research and development of pharmaceuticals and biopharmaceuticals for the treatment of cancer, hematological diseases, autoimmune diseases, and rare diseases; providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; genetic testing for scientific research; genetic research in the fields of oncology, hematology, autoimmune diseases, and rare diseases; none of the foregoing in relation to or in the field of fertility services

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, June 15, 2019
Primary Code042
First Use Anywhere DateThursday, April 20, 2017
First Use In Commerce DateThursday, April 20, 2017

Trademark Owner History


Party NamePrelude Therapeutics Incorporated
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWilmington, DE 198032907

Party NamePrelude Therapeutics Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWilmington, DE 198032907

Party NamePrelude Therapeutics Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWilmington, DE 198032907

Trademark Events


Event DateEvent Description
Tuesday, December 6, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 6, 2022REGISTERED-PRINCIPAL REGISTER
Tuesday, November 1, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, October 31, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, October 12, 2022STATEMENT OF USE PROCESSING COMPLETE
Thursday, September 29, 2022USE AMENDMENT FILED
Wednesday, October 12, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 29, 2022TEAS STATEMENT OF USE RECEIVED
Tuesday, May 10, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 15, 2022PUBLISHED FOR OPPOSITION
Wednesday, February 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, February 6, 2022ASSIGNED TO LIE
Friday, February 4, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 3, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 2, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, August 18, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, August 18, 2021FINAL REFUSAL E-MAILED
Wednesday, August 18, 2021FINAL REFUSAL WRITTEN
Thursday, January 14, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, June 24, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, December 20, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, December 20, 2019LETTER OF SUSPENSION E-MAILED
Friday, December 20, 2019SUSPENSION LETTER WRITTEN
Wednesday, December 4, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 3, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 3, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 23, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 23, 2019NON-FINAL ACTION E-MAILED
Friday, August 23, 2019NON-FINAL ACTION WRITTEN
Wednesday, August 21, 2019ASSIGNED TO EXAMINER
Monday, June 24, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, June 15, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 4, 2019NEW APPLICATION ENTERED